Response to hydroxyurea therapy in β-thalassemia

American Journal of Hematology

Volumn 83, Issue 5, 2008, Pages 366-370

  Koren, Ariel ^a,b   Levin, Carina ^a   Dgany, Orly ^c   Kransnov, Tatyan ^c   Elhasid, Ronit ^b,d   Zalman, Lucia ^a   Palmor, Haya ^a   Tamary, Hannah ^c,e  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d Mayer Medical Center   (Israel)

^e SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; HYDROXYUREA;

ADOLESCENT; ADULT; ALPHA THALASSEMIA; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TRANSFUSION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALPHA-THALASSEMIA; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; COHORT STUDIES; COMBINED MODALITY THERAPY; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DRUG EVALUATION; FEMALE; FETAL HEMOGLOBIN; GENOTYPE; GLOBINS; HEMOGLOBINS; HUMANS; HYDROXYUREA; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES;

EID: 42549112495     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21120     Document Type: Article

References (35)

1. Rund D, Rachmilewitz E. β-Thalassemia. N Engl J Med 2005;353:1135-1146.
2. Thein SL. Genetic insights into the clinical diversity of β thalassemia. Br J Haematol 2004;124:264-274.
3. Lowrey CH, Nienhuis AW. Brief report: Treatment with azacitidine of patients with end-stage β-thalassemia. N Engl J Med. 1993;329:845-848.
4. Letvin NL, Linch DC, Beardsley GP, et al. Augmentation of fetal-hemoglobin production in anemic monkeys by Hydroxyurea. N Engl J Med 1984;310:869-873.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
7. Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 1994;125:490-492.
8. Zeng YT, Huang SZ, Ren ZR, et al. Hydroxyurea therapy in β-thalassemia intermedia: improvement in haematological parameters due to enhanced β-globin synthesis. Br J Haematol 1995;90:557-563.
9. Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 1998;850:120-128.
10. Hoppe C, Vichinsky E, Lewis B, et al. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 1999;62:221-227.
11. de Paula EV, Lima CS, Arruda VR, et al. Long-term hydroxyurea therapy in β-thalassemia patients. Eur J Haematol 2003;70:151-155.
12. Konstantopoulos K, Vagiopoulos G, Kantouni R, et al. A case of spinal cord compression by extramedullar haemopoiesis in a thalassaemic patient: A putative role for hydroxyurea? Haematologica 1992;77:352-354.
13. Saxon BR, Rees D, Olivieri NF. Regression of extramedullar haemopoiesis and augmentation of fetal hemoglobin concentration during hydroxyurea therapy in β thalassemia. Br J Haematol 1998;101:416-419.
14. Wegener M, Debatin KM, Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullar hematopoiesis. Ann Hematol 2002;81:478-482.
15. Gamberini MR, Fortini M, De Sanctis V. Paraplegia due to spinal cord compression by extramedullar erythropoietic tissue in a thalassemia intermedia patient with gynecomastia secondary to cirrhosis: Successful treatment with Hydroxyurea. Pediatr Endocrinol Rev 2004; (Suppl 2):316-318.
16. Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/hemoglobin E disease. Blood 1996;87:887-892.
17. Singer ST, Kuypers FA, Olivieri NF, et al; E/β Thalassemia Study Group. Fetal hemoglobin augmentation in E/β(0) thalassemia: Clinical and haematological outcome Br J Haematol 2005;131:378-388.
18. Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood 2003;102:1529-1530.
19. Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica 2004; 89:1172-1178.
20. Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Haematol 2004;83:430-433.
21. Dixit A, Chatterjee TT, Mishra P, et al. Hydroxyurea in thalassemia intermedia - A promising therapy. Ann Hematol 2005;84:441-446.
22. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of Thalassemia Intermedia patients to hydroxyurea during 6 years of therapy in Iran. Pediatr Hematol Oncol 2005;27:380-385.
23. Panigrahi I, Dixit A, Arora S, et al. Do α-deletions influence hydroxyurea response in thalassemia intermedia? Hematology 2005;10:61-63.
24. Fathallah H, Sutton M, Atweh GF. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia? Ann N Y Acad Sci 2005;1054:228-237.
25. Taher A, Sheikh-Taha M. Hydroxyurea use in Lebanese patients with β-thalassemia intermedia. J Pediatr Hematol Oncol 2005;27:380-385.
26. Voscaridou E. Hydroxyurea (+ r-huEPO) in thalassemia. Proceedings of the 8th International Conference on Thalassemia and the Hemoglobinopath es, Athens, Greece, 2001. pp 76-77.
27. Wang M, Tang DC, Liu W, et al. Hydroxyurea exerts bi-modal dose dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 2002;119:1098-1105.
28. Cunningham JM, Jane SM. Hemoglobin switching and fetal hemoglobin reactivation. Semin Hematol 1996;33:9-23.
29. Briegel K, Bartunek P, Stengl G, et al. Regulation and function of transcription factor GATA-1 during red blood cell differentiation. Development 1996;122: 3839-3850.
30. Koren A, Segal-Kupershmit D, Attias D, et al. Effect of hydroxyurea in children and teenagers with severe sickle cell disease. Pediatr Haematol Oncol 1999; 16:221-232.
31. Amoyal I, Goldfarb A, Fibach E. Flow cytometric analysis of hydroxyurea effects on fetal hemoglobin production in cultures of β-thalassemia erythroid precursors. Hemoglobin 2003;27:77-87.
32. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003;102:3865-3870.
33. Tan JA, Tay JS, Lin LI, et al. The amplification refractory mutation system (ARMS): A rapid and direct prenatal diagnostic technique for beta-thalassemia in Singapore. Prenat Diagn 1994;14:1077-1082.
34. Tamary H, Surrey S, Kirschmann H, et al. Systemic use of automated fluorescence-based sequence analysis of amplified genomic DNA for rapid detection of point mutations. Am J Hematol 1994;46:127-133.
35. Chong SS, Boehm CD, Higgs DR, et al. Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia. Blood 2000;95:360-362.